Company intelligence / Profile preview

Azevan Pharmaceuticals

Bethlehem, Pennsylvania, United Statesazevan.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Completed two Phase II clinical trials with lead compound SRX246 for Intermittent Explosive Disorder and irritability in Huntington's Disease patients (STAIR trial). Both trials achieved primary endpoints and exploratory goals. SRX246 was generally well tolerated with no serious adverse events reported and clinical benefit observed on multiple scales. An additional Phase II clinical trial for PTSD is in progress.

Therapeutic areas: Women's HealthEndocrinologyPsychiatryNeurology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

4 assets

SRX246

3 more assets in the full pipeline.

Request access →

Partnerships

Department of DefenseWeill Cornell Medical College

Beyond the preview

Go deeper on Azevan Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Azevan Pharmaceuticals.

Explore the full profile